mTOR Signaling in Autophagy and Lysosomal Function

Introduction

The mechanistic target of rapamycin (mTOR) is the central negative regulator of autophagy, the cellular degradation pathway essential for clearing protein aggregates, damaged organelles, and cellular debris. In neurodegenerative diseases, mTOR hyperactivity impairs autophagy and lysosomal function, leading to the accumulation of toxic protein aggregates characteristic of Alzheimer’s disease, Parkinson’s disease, and related disorders^{1Autophagy in the pathogenesis and therapy of neurodegenerative diseases (2024)2024 · DOI 10.1016/j.tins.2024.01.001Open reference}. Understanding the mTOR-autophagy-lysosome axis provides critical insights into disease mechanisms and therapeutic targets.

mTOR Complexes and Autophagy Regulation

mTORC1 Structure and Function

mTORC1 (mTOR Complex 1) is the primary regulator of autophagy and consists of:

• mTOR: The catalytic serine/threonine kinase subunit

• Raptor: Regulatory protein that recruits substrates

• mLST8: Stabilizes the complex

• PRAS40 and Deptor: Negative regulators

mTORC1 integrates signals from:

• Nutrient status (amino acids, glucose)

• Growth factors (insulin, IGF-1)

• Energy levels (ATP/AMP ratio)

• Cellular stress (ER stress, oxidative stress)

mTORC1-Mediated Autophagy Inhibition

flowchart TD
    A["Nutrients/Growth Factors"]  -->  B["mTORC1 Activation"]
    B  -->  C["Phosphorylation Events"]
    C  -->  D["ULK1 Inhibition"]
    C  -->  E["TFEB Nuclear Exclusion"]
    C  -->  F["VPS34 Inhibition"]

    D  -->  G[" autophagy initiation blocked"]
    E  -->  H["lysosomal gene transcription blocked"]
    F  -->  I["autophagosome formation blocked"]

    G  -->  J["Protein aggregates accumulate"]
    H  -->  J
    I  -->  J

Key phosphorylation targets:

mTORC1 and Lysosomal Calcium Signaling

The intersection of mTOR signaling and lysosomal calcium dynamics is critical for autophagy regulation:

• Lysosomal calcium release activates calcineurin, which can dephosphorylate TFEB

• mTORC1 activity is modulated by lysosomal calcium through V-ATPase-dependent mechanisms^{2mTOR regulates lysosomal acidification and function2019 · Nature Cell Biology · DOI 10.1038/s41556-019-0349-7Open reference}

• Calcium dysregulation in neurodegeneration disrupts the mTOR-TFEB axis

• Store-operated calcium entry (SOCE) affects mTOR signaling in neurons^{3Lysosomal calcium in neurodegeneration: Mechanisms and therapeutic opportunities2023 · Cell Calcium · DOI 10.1016/j.ceca.2023.102723Open reference}

The TFEB-mTOR Axis

Transcription Factor EB (TFEB)

TFEB is the master regulator of lysosomal and autophagic gene expression. Under nutrient-rich conditions:

1. mTORC1 phosphorylates TFEB at Ser211

2. Phosphorylated TFEB binds to 14-3-3 proteins and remains cytoplasmic

3. Lysosomal and autophagy gene transcription is repressed

TFEB Activation and Neuroprotection

Upon nutrient deprivation or mTOR inhibition:

1. TFEB is dephosphorylated and translocates to nucleus

2. Binds to CLEAR (Coordinated Lysosomal Expression and Regulation) elements

3. Activates transcription of:

   • Autophagy genes: ATG proteins, LC3, p62/SQSTM1

   • Lysosomal genes: Cathepsins, V-ATPase, LAMP proteins

   • Biogenesis genes: TFEB itself, MITF family

flowchart LR
    subgraph TFEB_Activation
    A["mTOR Inhibition"]  -->  B["TFEB Dephosphorylation"]
    B  -->  C["TFEB Nuclear Translocation"]
    C  -->  D["Binding to CLEAR Elements"]
    D  -->  E["Gene Transcription"]
    end

    subgraph Autophagy_Lysosome_Boost
    E  -->  F["ATG Proteins up"]
    E  -->  G["Cathepsins up"]
    E  -->  H["LAMP Proteins up"]
    E  -->  I["V-ATPase up"]
    end

    subgraph Neuroprotective_Effects
    F  -->  J["Autophagosome Formation up"]
    G  -->  K["Lysosomal Degradation up"]
    H  -->  K
    I  -->  K
    J  -->  L["Protein Aggregate Clearance"]
    K  -->  L
    end

mTOR Dysregulation in Neurodegenerative Diseases

Alzheimer’s Disease

In AD, multiple mechanisms drive mTOR hyperactivity:

Key findings:

• Elevated p-mTOR in AD hippocampus and prefrontal cortex^{4mTOR hyperactivation in Alzheimer's disease brain correlates with cognitive decline (2023)2023 · DOI 10.1016/j.neurobiolaging.2023.02.004Open reference}

• mTOR hyperactivity correlates with cognitive decline

• Autophagic-lysosomal compartments accumulate in AD neurons

• Rapamycin and other mTOR inhibitors reduce Aβ and tau pathology in animal models

Parkinson’s Disease

In PD, mTOR dysregulation contributes to α-synuclein accumulation:

Therapeutic implications:

• Rapamycin protects dopaminergic neurons in PD models

• TFEB activation promotes α-synuclein clearance

• mTOR inhibitors combined with autophagy enhancers show promise

Amyotrophic Lateral Sclerosis

mTOR dysfunction in ALS contributes to TDP-43 aggregation:

• mTOR is sequestered in stress granules

• Autophagy inhibition leads to TDP-43 accumulation

• Motor neurons are particularly vulnerable to proteostasis failure

• RapaLink-1 shows promise in ALS models

Huntington’s Disease

In HD, mutant huntingtin affects mTOR signaling:

• Huntingtin disrupts mTORC1 localization

• Autophagy initiation is impaired

• p62 and aggregate clearance fails

mTOR and Lysosomal Calcium Dysregulation

Calcium homeostasis is critical for lysosomal function and autophagy regulation^{3Lysosomal calcium in neurodegeneration: Mechanisms and therapeutic opportunities2023 · Cell Calcium · DOI 10.1016/j.ceca.2023.102723Open reference}:

• Lysosomal calcium release activates calcineurin, which dephosphorylates TFEB

• mTORC1 activity is modulated by lysosomal calcium through V-ATPase-dependent mechanisms

• Calcium dysregulation in neurodegeneration disrupts the mTOR-TFEB axis

• Store-operated calcium entry (SOCE) affects mTOR signaling in neurons

mTORC1 and Lysosomal Acidification

Proper lysosomal acidification is essential for autophagic degradation^{2mTOR regulates lysosomal acidification and function2019 · Nature Cell Biology · DOI 10.1038/s41556-019-0349-7Open reference}:

• V-ATPase activity is regulated by mTORC1 through direct phosphorylation

• mTORC1 inhibition promotes lysosomal acidification and cathepsin activation

• Defective acidification contributes to protein aggregate accumulation in AD and PD

TFEB Nuclear Export in Cellular Stress

TFEB localization is dynamically regulated by cellular stress conditions^{5TFEB nuclear export in cellular stress and disease2023 · Nature Reviews Molecular Cell Biology · DOI 10.1038/s41580-023-00582-wOpen reference}:

• TFEB can shuttle between nucleus and cytoplasm in response to stress

• Nuclear export of TFEB is mediated by CRM1/exportin

• mTOR-independent TFEB activation pathways exist (e.g., via calcium/calcineurin)

• This provides therapeutic opportunities beyond mTOR inhibition

mTOR in Specific Neurodegenerative Contexts

Role in Amyloid-beta Metabolism

mTOR hyperactivation in AD affects APP processing and Aβ metabolism:

• mTORC1 promotes BACE1 translation, increasing Aβ production

• mTORC1 inhibits autophagy-mediated Aβ clearance

• Rapamycin treatment reduces Aβ levels in animal models

• Interaction between mTOR and γ-secretase complex

Role in Tau Pathology

mTOR signaling intersects with tau pathogenesis:

• mTORC1 activation promotes tau phosphorylation via GSK3β and CDK5

• Hyperphosphorylated tau further activates mTORC1

• This creates a vicious cycle of tau pathology and mTOR dysregulation

• mTOR inhibitors reduce tau pathology in models

Role in α-Synuclein Aggregation

In PD, mTOR dysregulation contributes to α-synuclein accumulation:

• Impaired autophagic clearance of α-synuclein

• LRRK2-mediated mTORC1 hyperactivation

• mTORC1 affects α-synuclein secretion and propagation

• TFEB activation promotes α-synuclein clearance

Role in TDP-43 Proteinopathy

In ALS/FTD, mTOR dysregulation contributes to TDP-43 aggregation:

• mTOR is sequestered in stress granules

• Autophagy inhibition leads to TDP-43 accumulation

• Motor neurons are particularly vulnerable to proteostasis failure

• Combined mTOR inhibition and autophagy enhancement shows promise

Emerging Therapeutic Approaches

G-quadruplex Targeting

G-quadruplexes in the MTOR mRNA regulate translation^{6G-quadruplexes in MTOR and induction of autophagy (2024)2024 · PMID 38291093Open reference}:

• Stabilization of MTOR mRNA G-quadruplex reduces mTOR translation

• This provides an alternative approach to mTOR inhibition

• Natural compounds targeting G-quadruplexes are being explored

Microglial mTOR Modulation

Microglial mTOR activity regulates neuroinflammation^{7Residual microglia following short-term PLX5622 treatment exhibit diminished NLRP3 inflammasome and mTOR signaling (2025)2025 · PMID 39571180Open reference}:

• PLX5622 (CSF1R antagonist) reduces microglial mTOR signaling

• Enhanced autophagy in microglia reduces NLRP3 inflammasome

• This represents a novel anti-inflammatory strategy

Natural Autophagy Activators

Natural compounds can activate autophagy through mTOR-independent pathways^{8Natural Autophagy Activators to Fight Age-Related Diseases (2024)2024 · PMID 39404375Open reference}:

• Spermidine induces autophagy via acetyltransferase inhibition

• Resveratrol activates autophagy through SIRT1

• Curcumin modulates multiple autophagy pathways

• These compounds may complement mTOR-targeted approaches

Novel Small Molecule Inhibitors

Next-generation mTOR inhibitors are in development:

• RapaLink-1: Third-generation rapalog with enhanced brain penetration

• AZD8055: ATP-competitive dual mTORC1/C2 inhibitor

• XL388: Allosteric mTORC1 inhibitor with improved selectivity

• Torin 2: Highly potent dual inhibitor for research applications

Combination Strategies

Combining mTOR inhibition with other approaches:

• mTOR + autophagy enhancers: Synergistic effects on protein clearance

• mTOR + TFEB activators: Dual promotion of lysosomal biogenesis

• mTOR + NLRP3 inhibitors: Targeting both autophagy and inflammation

• mTOR + metabolic modulators: Addressing multiple disease pathways

Clinical Trial Updates

Current clinical trials investigating mTOR modulation:

• Sirolimus in AD (NCT04658095)

• Everolimus in PD (NCT05565035)

• Rapamycin in ALS (NCT04412538)

• Novel TFEB activators in preclinical development

Biomarkers for mTOR Activity

Monitoring mTOR inhibition requires appropriate biomarkers:

• p-S6K1 (Thr389): Direct mTORC1 substrate phosphorylation

• p-S6 (Ser240/244): Downstream substrate in neurons

• p-4E-BP1 (Thr37/46): Translation repressor phosphorylation

• TFEB nuclear localization: Lysosomal biogenesis marker

• LC3-II/LC3-I ratio: Autophagy induction marker

• p62 turnover: Autophagic flux indicator

Cross-Disease Mechanisms

mTOR dysregulation is a shared mechanism across neurodegenerative diseases: